I

IsoPlexis

185 employees

IsoPlexis is a life science technology company that develops a single-cell detection system identifying patient immune responses.

Basic info

Industry

biotechnology research

Sectors

Immune Monitoring
Life Sciences
Medical Device
Biotechnology
Health Care
Therapeutics
Personalized Medicine
Microfluidics

Date founded

2013

Funding rounds raised

Total raised

$85M

from 16 investors over 16 rounds

I

IsoPlexis raised $85M on January 7, 2021

Investors: Perceptive Advisors

I

IsoPlexis raised $50M on January 7, 2021

Investors: Perceptive Advisors

I

IsoPlexis raised $20M on January 9, 2020

Investors: Spring Mountain Capital, Northpond Ventures, Ironwood Capital and Advantage Capital

I

IsoPlexis raised $2M on October 23, 2019

Investors: NCI SBIR Development Center

I

IsoPlexis raised $4M on June 21, 2019

Investors: NCI SBIR Development Center

I

IsoPlexis raised $25M on May 14, 2019

Investors: Spring Mountain Capital, Ironwood Capital, Northpond Ventures and Advantage Capital

I

IsoPlexis raised $14M on September 25, 2017

Investors: Spring Mountain Capital, Advantage Capital and Ironwood Capital

I

IsoPlexis raised undisclosed on November 3, 2016

Investors: Advantage Capital

FAQ